Consistent with this, Tavakoli Shirazi P et al. (2021) demonstrated that HDAC inhibitors, such as vorinostat or panobinostat, were effective against TYK2-rearranged B-ALL cells that had acquired cerdulatinib (a TYK2 inhibitor) resistance, demonstrating their potential therapeutic use [8]. This evidence concerns the gene HDAC9 and acute lymphoblastic leukemia.